AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + proprietary hiring database

✓Executive contact details included

INDUSTRY FIRST

Versameb Appoints Professor Roger Dmochowski As Chief Medical Officer

Jun 21, 2023•about 2 years ago

Position

Chief Medical Officer

Company

Versameb

Roger Dmochowski

BaselTherapeuticsBiotechnologyHealth Care

Description

Versameb AG , a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer with immediate effect.

Company Information

Company

Versameb

Location

Basel, Basel City, Switzerland

About

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on LinkedIn. SOURCE Versameb

Company News

(1 articles)

Thu, 20 Mar 2025 07:00:00 GMT

Versameb AG Announces Grant of First Patent in China for "Signal Peptide with Heterologous Protein" - Yahoo Finance

FundzWatch™ Score

Medium Activity

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months